DGAP-News: Prothena Shares to Be Added to Russell Global Index
(firmenpresse) - Prothena Corporation
17.06.2013 23:09
---------------------------------------------------------------------------
DUBLIN, Ireland, 2013-06-17 23:08 CEST (GLOBE NEWSWIRE) --
Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company
focused on the discovery and development of novel antibodies for the potential
treatment of a broad range of diseases, announced that the trading of its
ordinary shares will be included in the Russell Global Index when Russell
Investments reconstitutes its comprehensive set of U.S. and global equity
indexes on June 28, 2013, according to a preliminary list of additions posted
June 14, 2013 on www.russell.com/indexes.
Membership in the Russell Global Index, which remains in place for one year,
means automatic inclusion in the appropriate large-cap, small-cap, all-cap
indexes as well as the applicable style, sector and country indexes. Russell
determines membership for its equity indexes primarily by objective,
market-capitalization rankings and style attributes.
'We are very pleased to join the Russell Global Index' said Dale Schenk, PhD,
President and Chief Executive Officer of Prothena. 'It is well established that
investors rely on the Russell Indexes for true market representation and we
expect our inclusion to have many benefits, including increased liquidity and
broader exposure to institutional investors.'
Russell indexes are widely used by investment managers and institutional
investors for index funds and as benchmarks for both passive and active
investment strategies. According to Russell, approximately $4.1 trillion in
assets currently are benchmarked to Russell indexes.
The Russell Global Index, which Russell estimates captures approximately 98% of
investable securities globally, is reconstituted annually and all sub-indexes
are recalibrated to accurately measure current market realities for each market
segment. These investment tools originated from Russell's multi-manager
investment business in the early 1980s when the company saw the need for a more
objective, market-driven set of benchmarks in order to evaluate outside
investment managers.
Russell launched the Russell Global Index in 2007, leveraging the popular
methodology from its U.S. indexes. The broad-market Russell 3000(r) Index serves
as the U.S. component to the Russell Global Index.
Total returns data for the Russell Global Index and other Russell Indexes is
available at
http://www.russell.com/indexes/data/Global_Equity/Russell_Global_returns.asp.
About Russell
Russell Investments (Russell) is a global asset manager and one of only a few
firms that offers actively managed multi-asset portfolios and services that
include advice, investments and implementation. Russell stands with
institutional investors, financial advisors and individuals working with their
advisors--using the firm's core capabilities that extend across capital market
insights, manager research, portfolio construction, portfolio implementation
and indexes to help each achieve their desired investment outcomes.
Russell has more than $173 billion in assets under management (as of 3/31/2013)
and works with over 2,500 institutional clients, independent distribution
partners and individual investors globally. As a consultant to some of the
largest pools of capital in the world, Russell has $2.6 trillion in assets
under advisement (as of 12/31/2012). It has fourdecades of experience
researching and selecting investment managers and meets annually with more than
2,200 managers around the world. Russell traded more than $1.4 trillion in 2012
through its implementation services business.
About Prothena
Prothena Corporation plc is a clinical stage biotechnology company focused on
the discovery and development of novel antibodies for the potential treatment
of a broad range of diseases that involve protein misfolding and cell adhesion,
particularly on the discovery and development of potential therapeutic
monoclonal antibodies directed specifically to disease-causing proteins. These
potential therapies have a broad range of indications, including AL and AA
forms of amyloidosis (NEOD001), Parkinson's disease and related
synucleinopathies (PRX002) and novel cell adhesion targets involved in
inflammatory disease and metastatic cancers (PRX003).
For more information, please visit the company's web site at www.prothena.com.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of
the Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. These statements relate to, among other things, our
inclusion in the Russell Global Index and any anticipated benefits of increased
liquidity and broader exposure to institutional investors from having our
ordinary shares be included in the Russell Global Index, the. These
forward-looking statements are identified by their use of terms and phrases
such as 'anticipate,' 'believe,' 'could,' 'should,' 'estimate,' 'expect,'
'intend,' 'may,' 'plan,' 'predict,' 'project,' 'potential,' 'target,' 'will'
and similar terms and phrases, including references to assumptions. These
statements are based on assumptions that may not prove accurate. Actual results
could differ materially from those anticipated due to known and unknown risks,
uncertainties and other factors including, but not limited to the risks and
uncertainties described in the 'Risk Factors' section of our Annual Report on
Form 10-K filed with the SEC on March 29, 2013, the 'Risk Factors' section of
our Quarterly Reports on Form 10-Q that we file with the SEC from time to time.
Prothena undertakes no obligation to update publicly any forward-looking
statements contained in this press release as a result of new information,
future events or changes in Prothena's expectations.
CONTACT: Investors: Tran Nguyen, CFO
650-837-8535, IR(at)prothena.com
Media: Anita Kawatra
646-256-5116, anita.kawatra(at)prothena.com
News Source: NASDAQ OMX
17.06.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Prothena Corporation
United States
Phone:
Fax:
E-mail:
Internet:
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 17.06.2013 - 23:09 Uhr
Sprache: Deutsch
News-ID 270473
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 287 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Prothena Shares to Be Added to Russell Global Index"
steht unter der journalistisch-redaktionellen Verantwortung von
Prothena Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
